BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Sanovas, Inc. Receives Patent Allowance for Nested Balloon Catheter for Localized Drug Delivery


11/19/2012 9:05:22 AM

SAUSALITO, Calif., Nov. 19, 2012 /PRNewswire/ -- Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin Smart Catheter technology portfolio. The patent covers a unique minimally invasive system and method for delivering diagnostic and therapeutic agents to small diameter anatomy in the lungs and throughout the body.

"This patent is an important milestone in the protection of the company's proprietary drug delivery technologies," said Erhan Gunday, chief technology officer and co-founder of Sanovas. "With more than 45 patents and patents pending, Sanovas has built a strong IP portfolio for our micro-invasive diagnostics, devices and drug delivery technologies that poise to significantly advance the way pulmonary diseases, such as lung cancer, are detected and treated."

The nested balloon catheter patent, written by Sanovas founders Erhan Gunday and Larry Gerrans, will protect an integral part of the company's NanoVas drug delivery technology. The ability of new drug delivery systems, such as the nested balloon catheter for localized drug delivery, to deliver targeted, tumor-specific treatments, holds the potential for overcoming one of the greatest hurdles to chemotherapy systemic toxicity.

"As we advance the science of personalized medicine, the ability to deliver customized immune and gene therapy will transform the way cancer and chronic disease are treated. Sanovas is proud to be at the forefront of these significant advances," Gerrans said.

Sanovas' Vas Zeppelin Smart Catheter technology portfolio is designed to access, image, measure and diagnose anatomy in small airways and vessels residing at, or below, three millimeters in diameter. Featuring the world's smallest surgical camera, the Vas Zeppelin allows the removal of tumors and other obstructions and enables the local delivery of drug and immune therapies to patients suffering from lung cancer and related pulmonary and vascular diseases.

About Sanovas

Sanovas, Inc., based in Sausalito, Calif., is a life science technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies for unmet clinical needs. Sanovas' microsurgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body, enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. Privately held, Sanovas was founded by the pioneers in minimally invasive surgery. The company has more than 45 multi-national patents and patents pending.

Media Contacts:

Racepoint Group
For Sanovas
Marla Kertzman, 619-694-6701

SOURCE Sanovas, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->